An open-label study to evaluate the optimal dose of Xeloda [capecitabine] when combined with Eloxatin [oxaliplatin] and pre-operative pelvic irradiation in patients with locally advanced rectal cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms SOCRATES
- Sponsors Roche
- 21 Aug 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 01 Jun 2006 New trial record.